MedPath

Warfarin

Generic Name
Warfarin
Brand Names
Coumadin, Jantoven
Drug Type
Small Molecule
Chemical Formula
C19H16O4
CAS Number
81-81-2
Unique Ingredient Identifier
5Q7ZVV76EI
Background

Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral anticoagulant in North America. Warfarin has several properties that should be noted when used medicinally, including its ability to cross the placental barrier during pregnancy which can result in fetal bleeding, spontaneous abortion, preterm birth, stillbirth, and neonatal death. Additional adverse effects such as necrosis, purple toe syndrome, osteoporosis, valve and artery calcification, and drug interactions have also been documented with warfarin use. Warfarin does not actually affect blood viscosity, rather, it inhibits vitamin-k dependent synthesis of biologically active forms of various clotting factors in addition to several regulatory factors.

Indication

Indicated for:

1) Prophylaxis and treatment of venous thromboembolism and related pulmonary embolism.

2) Prophylaxis and treatment of thromboembolism associated with atrial fibrillation.

3) Prophylaxis and treatment of thromboembolism associated with cardiac valve replacement.

4) Use as adjunct therapy to reduce mortality, recurrent myocardial infarction, and thromboembolic events post myocardial infarction.

Off-label uses include:

1) Secondary prevention of stroke and transient ischemic attacks in patients with rheumatic mitral valve disease but without atrial fibrillation.

Associated Conditions
Myocardial Infarction, Pulmonary Embolism, Stroke, Systemic Embolism, Thromboembolism, Transient Ischemic Attack, Venous Thrombosis (Disorder)
Associated Therapies
-

Prevention of Venous Thrombosis After Permanent Transvenous Leads Implantation

Not Applicable
Completed
Conditions
Cardiac Pacing
Complications
Venous Thrombosis
Interventions
First Posted Date
2008-02-22
Last Posted Date
2012-10-26
Lead Sponsor
University of Sao Paulo
Target Recruit Count
101
Registration Number
NCT00621491
Locations
🇧🇷

Heart Institute (InCor) - Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo, Sao Paulo, SP, Brazil

A Study to Evaluate the Safety and Efficacy of YM150 in Patients With Knee Replacement Surgery

Phase 2
Completed
Conditions
Arthroplasty, Replacement, Knee
Interventions
First Posted Date
2008-01-16
Last Posted Date
2013-03-25
Lead Sponsor
Astellas Pharma Inc
Target Recruit Count
685
Registration Number
NCT00595426

Evaluation of Weekly Idrabiotaparinux Sodium Versus Oral Adjusted-dose Warfarin to Prevent Stroke and Systemic Thromboembolic Events in Patients With Atrial Fibrillation

Phase 3
Terminated
Conditions
Atrial Fibrillation
Interventions
Drug: Idrabiotaparinux sodium
Drug: Warfarin
Drug: Placebo (for warfarin)
Drug: Placebo (for idrabiotaparinux)
Drug: Placebo (for avidin)
Drug: Avidin
First Posted Date
2007-12-24
Last Posted Date
2016-03-21
Lead Sponsor
Sanofi
Target Recruit Count
3773
Registration Number
NCT00580216
Locations
🇺🇸

Sanofi-Aventis Investigational Site Number 840128, Philadelphia, Pennsylvania, United States

🇺🇸

Sanofi-Aventis Investigational Site Number 840181, Pittsburgh, Pennsylvania, United States

🇺🇸

Sanofi-Aventis Investigational Site Number 840146, Cleveland, Ohio, United States

and more 535 locations

Duloxetine - Warfarin Pharmacodynamic Study

Phase 1
Completed
Conditions
Anticoagulant Effect of Warfarin When Taken With Duloxetine.
Interventions
First Posted Date
2007-09-21
Last Posted Date
2008-10-02
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
60
Registration Number
NCT00533026
Locations
🇬🇧

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559), Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician, Leeds, West Yorkshire, United Kingdom

A Study to Assess the Safety of a Potential New Drug in Comparison to the Standard Practice of Dosing With Warfarin for Non-valvular Atrial Fibrillation

Phase 2
Completed
Conditions
Atrial Fibrillation
Thromboembolism
Interventions
First Posted Date
2007-07-20
Last Posted Date
2019-02-26
Lead Sponsor
Daiichi Sankyo
Target Recruit Count
1146
Registration Number
NCT00504556

Efficacy and Safety of Rivaroxaban for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation

First Posted Date
2007-07-02
Last Posted Date
2015-04-20
Lead Sponsor
Bayer
Target Recruit Count
1280
Registration Number
NCT00494871

Interaction Between ABT-335, Rosuvastatin and Warfarin

First Posted Date
2007-06-15
Last Posted Date
2012-09-28
Lead Sponsor
AstraZeneca
Target Recruit Count
45
Registration Number
NCT00487136
Locations
🇺🇸

Site Ref # / Investigator 5290, Little Rock, Arkansas, United States

Modeling Genotype and Other Factors to Enhance the Safety of Coumadin Prescribing

Not Applicable
Conditions
Atrial Fibrillation
Deep Venous Thrombosis
Heart Valve Replacement
Pulmonary Embolism
First Posted Date
2007-06-11
Last Posted Date
2007-06-11
Lead Sponsor
Agency for Healthcare Research and Quality (AHRQ)
Target Recruit Count
260
Registration Number
NCT00484640
Locations
🇺🇸

Marshfield Clinic, Marshfield, Wisconsin, United States

🇺🇸

Third Wave Molecular Diagnostics, Madison, Wisconsin, United States

Anticoagulant Therapy During Pacemaker Implantation

Phase 4
Completed
Conditions
Hemorrhage
Thrombosis
Embolism
Interventions
Drug: Warfarin
Drug: Aspirin
Device: Permanent pacemaker
Device: Implantable Cardioverter-defibrillator
First Posted Date
2007-05-28
Last Posted Date
2012-09-17
Lead Sponsor
University of Turku
Target Recruit Count
447
Registration Number
NCT00479362
Locations
🇫🇮

Turku University Hospital, Turku, Finland

Direct Factor Xa Inhibitor YM150 for Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation

Phase 2
Completed
Conditions
Atrial Fibrillation
Interventions
First Posted Date
2007-03-16
Last Posted Date
2011-12-19
Lead Sponsor
Astellas Pharma Inc
Target Recruit Count
448
Registration Number
NCT00448214
© Copyright 2025. All Rights Reserved by MedPath